Khanam Farhana, Babu Golap, Rahman Nazia, Liu Xinxue, Rajib Nazmul Hasan, Ahmed Shams Uddin, Hossen Md Ismail, Biswas Prasanta Kumar, Kelly Sarah, Thesis-Nyland Katherine, Mujadidi Yama, McMillan Nigel A J, Pollard Andrew J, Clemens John D, Qadri Firdausi
International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh; Menzies Health Institute Queensland and School of Pharmacy and Medical Science, Griffith University, Gold Coast, Australia.
International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.
Vaccine. 2023 May 5;41(19):3137-3140. doi: 10.1016/j.vaccine.2023.04.014. Epub 2023 Apr 13.
A cluster-randomized trial of Vi-TT was conducted in Dhaka, Bangladesh, using JE vaccine as the control. A subset of 1,500 children were randomly selected on 2:1 basis (Vi-TT vs JE) to assess immune response. Blood was collected before vaccination, and on days 28, 545 and 730 post-vaccination and plasma anti-Vi-IgG response was measured. A robust, persistent antibody response was induced after single dose of Vi-TT, even after 2 years of vaccination. While there is no accepted serological antibody threshold of protection, analyzing the antibodies of children who received Vi-TT provides evidence that may later be useful in predicting population protection.
在孟加拉国达卡进行了一项以日本脑炎(JE)疫苗为对照的Vi-TT(Vi多糖疫苗)整群随机试验。按照2:1的比例(Vi-TT组与JE组)随机挑选了1500名儿童的一个子集,以评估免疫反应。在接种疫苗前、接种后第28天、第545天和第730天采集血液,并检测血浆抗Vi-IgG反应。单剂量Vi-TT接种后可诱导出强劲、持久的抗体反应,即使在接种2年后也是如此。虽然目前尚无公认的血清学抗体保护阈值,但分析接种Vi-TT儿童的抗体可为日后预测群体保护提供有用证据。